scholarly journals Microbiological analyses of nasally guided catheters after less invasive surfactant administration – a pilot study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Christian A. Maiwald ◽  
Julia Dick ◽  
Matthias Marschal ◽  
Christian Gille ◽  
Axel R. Franz ◽  
...  
1997 ◽  
Vol 4 (1) ◽  
pp. 21-26 ◽  
Author(s):  
James F Lewis ◽  
Jasvinder S Dhillon ◽  
Ram N Singh ◽  
Craig C Johnson ◽  
Timothy C Frewen

Exogenous surfactant administration is currently being tested in patients with the acute respiratory distress syndrome (ARDS). The results of the studies have varied because several factors may influence the host’s response to this therapy. This clinical pilot study was designed to evaluate the safety and efficacy of exogenous surfactant administration in pediatric patients with ARDS. Surfactant was administered to 13 patients with severe lung dysfunction, and eight of these patients experienced a significant improvement in oxygenation after the first dose of surfactant. In these patients the exogenous surfactant was administered within 48 h of the diagnosis of ARDS, whereas in the five patients who did not respond, surfactant was administered several days after the onset of ARDS. Responders also spent fewer days on a mechanical ventilator and less time in intensive care compared with nonresponders. Based on the results of this pilot study, a more appropriate multicentre clinical trial should be designed to evaluate this treatment strategy.


2018 ◽  
Vol 107 (5) ◽  
pp. 780-783 ◽  
Author(s):  
Laura Fabbri ◽  
Katrin Klebermass-Schrehof ◽  
Marta Aguar ◽  
Catherine Harrison ◽  
Ewa Gulczyńska ◽  
...  

2018 ◽  
Vol 35 (06) ◽  
pp. 530-533 ◽  
Author(s):  
Ilia Bresesti ◽  
Laura Fabbri ◽  
Gianluca Lista

AbstractIn the 1990s, the most relevant pillars in the treatment of neonatal respiratory distress syndrome (RDS) have been improvements in ventilation strategies, the introduction of exogenous surfactant replacement therapy, and the use of antenatal steroids. Lately, in addition to the standard INSURE (INtubation–SURfactant administration–Extubation) method to administer surfactant, a new technique has been gaining increasing popularity. It is the so-called less invasive surfactant administration (LISA) method, which has shown promising results in preventing bronchopulmonary dysplasia development and in reducing mortality in preterm neonates. The rationale behind this technique is to avoid positive pressure ventilation and the endotracheal tube, being surfactant delivered through a thin catheter while the neonate is maintained on continuous positive airway pressure. Given the paucity of large-scale randomized trials on LISA method to prove its effects on short- and long-term outcomes, some questions still remain unanswered. Then, uncertainty regarding the feasibility of this maneuver needs to be better clarified before gaining wide acceptance in routine clinical practice. In our report, we aim at hypothesizing the main mechanisms behind the efficacy of LISA, considering it as a single maneuver in a comprehensive approach for RDS management in the delivery room.


Author(s):  
Christian Achim Maiwald ◽  
Patrick Neuberger ◽  
Axel R Franz ◽  
Corinna Engel ◽  
Matthias Vochem ◽  
...  

BackgroundLess-invasive surfactant administration (LISA) is increasingly used. We investigated the feasibility of a new LISA-device (Neofact®) in neonates.DesignProspective observational pilot study with open-label LISA in two tertiary neonatal intensive care units.Patients20 infants with a gestational age of ≥26+0/7 weeks and an indication for LISA (Respiratory Severity Score (RSS)≥5 or fraction of inspired oxygen (FiO2) ≥0.30). Infants with respiratory tract malformations or unavailability of an instructed neonatologist were excluded.Main outcome measuresSuccess of LISA, defined as laryngoscopy-confirmed intratracheal catheter position or a decrease in FiO2 by ≥0.05 or to 0.21, accompanied by an RSS decrease of ≥2; number of attempts needed for tracheal catheterisation.Results20/57 screened infants were enrolled. Successful application occurred in 19/20 (95%). One application failed after three attempts. No device-related adverse events occurred. The median number of attempts was 2, success rate per attempt 19/31 (61%).ConclusionLISA via Neofact® appears feasible.


2019 ◽  
Vol 39 (3) ◽  
pp. 426-432 ◽  
Author(s):  
Dalibor Kurepa ◽  
Shahana Perveen ◽  
Yisrael Lipener ◽  
Venkatakrishna Kakkilaya

2020 ◽  
Vol 202 (5) ◽  
pp. 766-769
Author(s):  
Walusa Assad Gonçalves-Ferri ◽  
Felipe S. Rossi ◽  
Eduardo L. V. Costa ◽  
Letícia Correa ◽  
Daniela Iope ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document